CSCI Stock — COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc. (CSCI)

Updated September 18, 2026.

CSCI is a Stock. Its deepest 1-year drawdown was 76.8%.

COSCIENS Biopharma Inc. is a life science company that develops and commercializes products across cosmeceutical, nutraceutical, and pharmaceutical markets. Its portfolio includes active ingredients such as oat beta glucan and yeast-derived beta glucan for consumer health applications, as well as Macrilen/Ghryvelin, a pharmaceutical product for diagnosing growth hormone deficiency. The company does not currently distribute to shareholders.

CSCI performance

Returns are updating. CSCI's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 76.8%.

CSCI key facts

Asset type

Stock

Asset class

Equity

Inception date

05/10/2000

Distribution frequency

None

Last close

$7.60 (stale; as of 2026-09-18)

Market cap

$24,145,504

Average volume

100.0

Beta

1.852

Payout ratio

0.0%

EPS

$-6.54

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CSCI risks and drawbacks

The deepest 1-year drawdown on record here is 76.8%.

Who may consider CSCI — and who may not

It is a weaker fit for investors who need monthly cash flow (CSCI does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CSCI

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions